CORDIS · 820820 · H2020
MOBILISE-D Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
Coordinator: UNIVERSITY OF NEWCASTLE UPON TYNE (UK)
Optimal treatment of the impaired mobility resulting from ageing and chronic disease is one of the 21st century's greatest challenges facing patients, society, governments, healthcare services, and science. New interventions are a key focus. However, to accelerate their development, we need better ways to detect and measure mobility loss. Digital technology, including body worn sensors, has the potential to revolutionise mobility assessment. The overarching objectives of MOBILISE-D are threefold: to deliver a valid solution (consisting of sensor, algorithms, data analytics, outcomes) for real…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €25.4M awarded to the consortium. The project runs over approximately 5.2 years from 2019-04-01 to 2024-06-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from UK
see all →- ENABLE — European Gram Negative Antibacterial Engine115583 · FP7 · €58.9M
- EBOVAC1 — Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854115854 · H2020 · €58.3M
- CRESCENDO — Collaborative & Robust Engineering using Simulation Capability Enabling Next Design Optimisation234344 · FP7 · €32.5M
- H2ME — Hydrogen Mobility Europe671438 · H2020 · €32.0M
- JIVE — Joint Initiative for hydrogen Vehicles across Europe735582 · H2020 · €32.0M
- LIGAND-AI — Protein-ligand data generation at scale to support computational hit finding and optimization101252959 · HORIZON · €29.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €25.4M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-JTI-IMI2-2017-13-two-stage.
- Who coordinates the project?
- The project is coordinated by UNIVERSITY OF NEWCASTLE UPON TYNE (UK).
- What is the project timeline?
- The project runs from 2019-04-01 to 2024-06-30 — approximately 5.2 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 820820.